On June 29, XtalPi Holdings rose 6.07% in regular trading, trading at 7.25 HKD/share, with turnover of 231 million HKD.

On the news front, the company has recently released a cluster of positive developments. XtalPi announced a strategic partnership with an international biopharmaceutical company to co-develop oral small-molecule therapies targeting G protein-coupled receptors (GPCR), with a potential deal value exceeding $400 million including upfront payments, research funding, development and commercial milestone payments, and future royalties. The partner will fully fund XtalPi's early-stage R&D work. Simultaneously, the company launched a $100 million share buyback plan effective from June 10, signaling management confidence in the stock's valuation.

Additionally, national-level policy deployment for data-empowered AI development has boosted market expectations for a revaluation of the company's physical AI infrastructure capabilities. The broader life sciences sector rallied in tandem, with WuXi Biologics up 4.54%, Pharmaron up 4.57%, WuXi AppTec up 3.03%, and WuXi XDC up 3.27%, providing further sector-wide momentum.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)